Literature DB >> 18842607

Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users.

Maartje M L de Win1, Gerry Jager, Jan Booij, Liesbeth Reneman, Thelma Schilt, Cristina Lavini, Sílvia D Olabarriaga, Gerard J den Heeten, Wim van den Brink.   

Abstract

Previous studies have suggested toxic effects of recreational ecstasy use on the serotonin system of the brain. However, it cannot be excluded that observed differences between users and non-users are the cause rather than the consequence of ecstasy use. As part of the Netherlands XTC Toxicity (NeXT) study, we prospectively assessed sustained effects of ecstasy use on the brain in novel ecstasy users using repeated measurements with a combination of different neuroimaging parameters of neurotoxicity. At baseline, 188 ecstasy-naive volunteers with high probability of first ecstasy use were examined. After a mean period of 17 months follow-up, neuroimaging was repeated in 59 incident ecstasy users and 56 matched persistent ecstasy-naives and their outcomes were compared. Neuroimaging included [(123)I]beta-carbomethoxy-3beta-(4-iodophenyl)tropane (CIT) SPECT to measure serotonin transporter densities as indicators of serotonergic function; (1)H-MR spectroscopy ((1)H-MRS) to measure brain metabolites as indicators of neuronal damage; diffusion tensor imaging (DTI) to measure the apparent diffusion coefficient and fractional anisotropy (FA) of the diffusional motion of water molecules in the brain as indicators of axonal integrity; and perfusion weighted imaging (PWI) to measure regional relative cerebral blood volume (rrCBV) which indicates brain perfusion. With this approach, both structural ((1)H-MRS and DTI) and functional ([(123)I]beta-CIT SPECT and PWI) aspects of neurotoxicity were combined. Compared to persistent ecstasy-naives, novel low-dose ecstasy users (mean 6.0, median 2.0 tablets) showed decreased rrCBV in the globus pallidus and putamen; decreased FA in thalamus and frontoparietal white matter; increased FA in globus pallidus; and increased apparent diffusion coefficient in the thalamus. No changes in serotonin transporter densities and brain metabolites were observed. These findings suggest sustained effects of ecstasy on brain microvasculature, white matter maturation and possibly axonal damage due to low dosages of ecstasy. Although we do not know yet whether these effects are reversible or not, we cannot exclude that ecstasy even in low doses is neurotoxic to the brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842607     DOI: 10.1093/brain/awn255

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  24 in total

1.  Methodological weaknesses in non-randomized studies of ecstasy (MDMA) use: a cautionary note to readers and reviewers.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  Neuropsychopharmacology       Date:  2012-03       Impact factor: 7.853

2.  Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study.

Authors:  John Karageorgiou; Mary S Dietrich; Evonne J Charboneau; Neil D Woodward; Jennifer U Blackford; Ronald M Salomon; Ronald L Cowan
Journal:  Neuroimage       Date:  2009-03-02       Impact factor: 6.556

Review 3.  Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.

Authors:  Stephanie C Licata; Perry F Renshaw
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

5.  Decision-making in polydrug amphetamine-type stimulant users: an fMRI study.

Authors:  Philip Koester; Kirsten G Volz; Marc Tittgemeyer; Daniel Wagner; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Joerg Daumann
Journal:  Neuropsychopharmacology       Date:  2013-02-07       Impact factor: 7.853

6.  Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Authors:  Stephen J Kish; Jason Lerch; Yoshiaki Furukawa; Junchao Tong; Tina McCluskey; Diana Wilkins; Sylvain Houle; Jeffrey Meyer; Emanuela Mundo; Alan A Wilson; Pablo M Rusjan; Jean A Saint-Cyr; Mark Guttman; D Louis Collins; Colin Shapiro; Jerry J Warsh; Isabelle Boileau
Journal:  Brain       Date:  2010-05-17       Impact factor: 13.501

Review 7.  Are there volumetric brain differences associated with the use of cocaine and amphetamine-type stimulants?

Authors:  Scott Mackey; Martin Paulus
Journal:  Neurosci Biobehav Rev       Date:  2012-12-17       Impact factor: 8.989

8.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

9.  MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus.

Authors:  John H Anneken; Gary A Gudelsky
Journal:  Neuropharmacology       Date:  2012-07-25       Impact factor: 5.250

Review 10.  The Utility of Magnetic Resonance Spectroscopy for Understanding Substance Use Disorders: A Systematic Review of the Literature.

Authors:  Tracy Hellem; Xianfeng Shi; Gwen Latendresse; Perry F Renshaw
Journal:  J Am Psychiatr Nurses Assoc       Date:  2015 Jul-Aug       Impact factor: 2.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.